# Treatment of Patients With Blepharitis and Facial Rosacea

> **NCT00560703** · PHASE2 · COMPLETED · sponsor: **Galderma R&D** · enrollment: 70 (actual)

## Conditions studied

- Blepharitis
- Meibomianitis
- Dry Eye

## Interventions

- **DRUG:** COL-101 (doxycycline, USP) capsules
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00560703
- **Lead sponsor:** Galderma R&D
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2009-05
- **Final completion:** 2009-07
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2021-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00560703

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00560703, "Treatment of Patients With Blepharitis and Facial Rosacea". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00560703. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*